2020
Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase
Chien Y, Hwu H, Hwang T, Hsieh M, Liu C, Lin-Shiau S, Liu C. Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2020, 99: 109868. PMID: 31954755, DOI: 10.1016/j.pnpbp.2020.109868.Peer-Reviewed Original ResearchConceptsChronic stable schizophreniaNon-psychiatric controlsDisorganized symptomsChronic stable patientsStable schizophreniaWeeks of antipsychotic treatmentStages of schizophreniaAcute relapseClinical implicationsAntipsychotic treatmentNegative symptomsSchizophreniaStable patientsOxidative stressPlatelet superoxide dismutasePlatelet oxidative stressTreatment responseNitric oxideLipid peroxidationLevels of nitric oxideSymptomsSuperoxide dismutaseTreatment effectsRelapsed patientsRelapse
2018
Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases
Liu C, Lin Y, Liu C, Hsieh M, Chien Y, Hwang T, Hwu H. Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases. Early Intervention In Psychiatry 2018, 13: 895-901. PMID: 29927087, DOI: 10.1111/eip.12696.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisLong-term antipsychotic treatmentAntipsychotic treatmentRecurrence of psychotic symptomsCourse of chronic schizophreniaLow-dose antipsychoticsChronic schizophreniaDysthymic statesPsychotic symptomsDiagnostic stabilityWord lettersRemission criteriaPsychosisAmbiguous informationProbability of relapseCoping strategiesImpending relapseAmbiguous outcomesDiscontinued medicationAntipsychoticsPersonalized formulationsMedication adherencePsychosocial factorsEarly interventionGroup of patients
2012
Hypomania Associated With Adjunctive Aripiprazole in an Elder Female With Recurrent Major Depressive Disorder
Lin H, Lin C, Liu C. Hypomania Associated With Adjunctive Aripiprazole in an Elder Female With Recurrent Major Depressive Disorder. Journal Of Clinical Psychopharmacology 2012, 32: 836-837. PMID: 23131891, DOI: 10.1097/jcp.0b013e318272d2b7.Peer-Reviewed Original ResearchCC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Firpi R, Dong H, Clark V, Soldevila‐Pico C, Morelli G, Cabrera R, Norkina O, Shuster J, Nelson D, Liu C. CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International 2012, 33: 72-78. PMID: 23107586, PMCID: PMC3518691, DOI: 10.1111/liv.12013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsBiopsyFemaleFloridaGenotypeHepatitis CHumansInterferonsInterleukinsKaplan-Meier EstimateLiver CirrhosisLiver TransplantationLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsTreatment OutcomeConceptsSustained viral responseInterferon-based therapyLiver transplant patientsCC genotypeRecurrent HCVLiver transplantTransplant patientsIL-28B single nucleotide polymorphismInterleukin (IL) 28B single nucleotide polymorphismsAdult liver transplant patientsPost-transplant HCV recurrenceHepatitis C populationIL-28B genotypeIL-28B polymorphismsInterleukin 28B (IL28B) polymorphismsStrongest pretreatment predictorOverall clinical outcomeBetter treatment responseSingle nucleotide polymorphismsHCV recurrenceHCV patientsHCV therapyLiver transplantationHepatitis COverall survival
2004
One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplantSustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Abdelmalek M, Firpi R, Soldevila‐Pico C, Reed A, Hemming A, Liu C, Crawford J, Davis G, Nelson D. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 2004, 10: 199-207. PMID: 14762857, DOI: 10.1002/lt.20074.Peer-Reviewed Original ResearchConceptsHepatitis C virusLiver transplant recipientsTransplant recipientsHepatitis CLiver histologyFibrosis stageHCV RNAViral clearanceViral responseCombination therapyDetectable hepatitis C virusRecurrent chronic hepatitis CRecurrent hepatitis C infectionRecurrent hepatitis C virusDetectable HCV RNASustained viral responseChronic hepatitis CInterferon-based treatmentOrthotopic liver transplantationRecurrent hepatitis CHepatitis C infectionInterferon-based therapyRegression of fibrosisGrade of inflammationBaseline histology
2002
Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
Firpi R, Abdelmalek M, Soldevila‐Pico C, Reed A, Hemming A, Howard R, van der Werf W, Lauwers G, Liu C, Crawford J, Davis G, Nelson D. Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplantation 2002, 8: 1000-1006. PMID: 12424712, DOI: 10.1053/jlts.2002.34968.Peer-Reviewed Original ResearchConceptsInterferon alfa-2bLiver transplantationAlfa-2bHistological recurrenceViral eradicationHCV RNAWeek 24Recurrent hepatitis C virus (HCV) infectionHCV RNA 6 monthsHepatitis C virus infectionEnd pointProgressive cholestatic diseaseRecurrent HCV infectionSerum HCV RNAC virus infectionLiver transplant recipientsPrimary end pointRecurrent hepatitis CSecondary end pointsGenotype 1 infectionYears of therapyEnd of treatmentHigh viral loadLiver biopsy resultsRecurrent HCV